|
|
| (One intermediate revision by the same user not shown) |
| Line 1: |
Line 1: |
| {{familytree/start |summary=PE diagnosis Algorithm.}} | | {{familytree/start |summary=PE diagnosis Algorithm.}} |
| {{familytree | | | | | | | | | |,|-| A01 | | | | |A01= | | {{familytree | | | | | | | | |,|-| A01 | | | | |A01= |
| <div style="width: 20em; padding:0em;text-align:left"> | | <div style="width: 20em; padding:0em;text-align:left"> |
| * '''INSS stage 1'''<br> | | *'''INNS stage 2A/2B, Stage 3 , Stage 4 or Stage 4S'''<br> |
| *'''Irrespective of age'''<br>
| |
| *'''Irrespective of grade'''<br>
| |
| *'''Irrespective of molecular pathway'''</div>}}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | C01 |-|+|-| B01 | | | | |C01=<div style="width: 20em; padding:0em;text-align:center">'''Low risk neuroblastoma patients'''</div>|B01=<div style="width: 20em; padding:0em;text-align:left">
| |
| *'''INSS stage 2A/2B (>50% resected)'''<br>
| |
| *'''Irrespective of age'''<br> | | *'''Irrespective of age'''<br> |
| *'''Irrespective of grade'''<br> | | *'''Irrespective of grade'''<br> |
| | *'''''MYCN'' amplified'''</div>}} |
| | {{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} |
| | {{familytree | | | | | | | | |)|-| B01 | | | | ||B01=<div style="width: 20em; padding:0em;text-align:left"> |
| | *'''INSS stage 3'''<br> |
| | *'''>547 days of age'''<br> |
| | *'''Unfavorable histology'''<br> |
| *'''''MYCN'' not amplified'''</div>}} | | *'''''MYCN'' not amplified'''</div>}} |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | | {{familytree | | | | | C01 |-|(| | | | | |C01=<div style="width: 20em; padding:1em;text-align:center">'''Intermediate risk neuroblastoma patients (group 2)'''</div> | | | | | | | | | | | | }} |
| {{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | | {{familytree | | | | | | | | | )|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> |
| *'''INNS stage 4S'''<br> | | *'''INNS stage 4'''<br> |
| *'''<365 days of age'''<br> | | *'''365-547 days of age'''<br> |
| *'''Favorable histology'''<br> | | *'''Unfavorable histology'''<br> |
| *'''DNA index >1'''<br> | | *'''DNA index=1'''<br> |
| *'''''MYCN'' not amplified'''</div>}} | | *'''''MYCN'' not amplified'''</div>}} |
| | {{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | }} |
| | {{familytree | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> |
| | *'''Symptomatic INNS stage 4'''<br> |
| | *'''>547 days of age'''<br> |
| | *'''Irrespective grade'''<br> |
| | *'''Irrespective ''MYCN'' amplification state'''</div>}} |
| {{familytree/end}} | | {{familytree/end}} |
| <br>
| |
|
| |
| {{familytree/start |summary=PE diagnosis Algorithm.}}
| |
| {{familytree | | | | | | | | | |,|-| A01 | | | | |A01=
| |
| <div style="width: 20em; padding:0em;text-align:left">
| |
| * '''INSS stage 1'''<br>
| |
| *'''Irrespective of age'''<br>
| |
| *'''Irrespective of grade'''<br>
| |
| *'''Irrespective of molecular pathway'''</div>}}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | |)|-| B01 | | | | ||B01=<div style="width: 20em; padding:0em;text-align:left">
| |
| *'''INSS stage 2A/2B (>50% resected)'''<br>
| |
| *'''Irrespective of age'''<br>
| |
| *'''Irrespective of grade'''<br>
| |
| *'''''MYCN'' not amplified'''</div>}}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | C01 |-|(| | | | | |C01=<div style="width: 20em; padding:1em;text-align:center">'''Intermediate risk neuroblastoma patients (group 1)'''</div> | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | |)|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left">
| |
| *'''INNS stage 4S'''<br>
| |
| *'''<365 days of age'''<br>
| |
| *'''Favorable histology'''<br>
| |
| *'''DNA index >1'''<br>
| |
| *'''''MYCN'' not amplified'''</div>}}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left">
| |
| *'''INNS stage 4S'''<br>
| |
| *'''<365 days of age'''<br>
| |
| *'''Favorable histology'''<br>
| |
| *'''DNA index >1'''<br>
| |
| *'''''MYCN'' not amplified'''</div>}}
| |
| {{familytree/end}}
| |
| <br>
| |
| {{familytree/end}}
| |
| <br>
| |
|
| |
| {{familytree/start |summary=PE diagnosis Algorithm.}}
| |
| {{familytree | | | | | | | | | |,|-| A01 | | | | | | |A01= | |}}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | |)|-| B01 | | | | | | |B01= | | }}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | C01 |-|(| | | | | | | | | |C01= | | | }}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | |)|-| D01 | | | | | | |D01= | | }}
| |
| {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }}
| |
| {{familytree | | | | | | | | | |`|-| E01 | | | | | | |E01= | |}}
| |
|
| |
|
| |
|
| |
| Intermediate risk neuroblastoma patients include:
| |
|
| |
|
| Group 1
| |
|
| |
|
| Patients with stage 2A/2B (<50% resected or Bx only) tumor, 0-12 years of age, irrespective of the grade, MYCNnot amplified
| |
| Patients with stage 3 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified
| |
| Patients with stage 3 tumor, 1-12 years of age, favorable histology, MYCNnot amplified
| |
| Patients with symptomatic stage 4S, <365 days of age, favorable histology, DNA index >1, MYCNnot amplified
| |
|
| |
|
| Group 2
| |
|
| |
|
| Patients with stage 3 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified
| |
| Patients with stage 4 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified
| |
| Patients with stage 4S tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified
| |
|
| |
|
| Group 3
| |
|
| |
|
| Patients with stage 4 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified | | * '''High risk neuroblastoma patients''' include: |
| Patients with stage 3 tumor, 365-547 days of age, unfavorable histology, MYCN not amplified | | :* Patients with stage 2A/2B, 3, 4, or 4S tumor, irrespective of the age, irrespective of the grade, ''MYCN'' amplified |
| Patients with stage 4 tumor, 365-547 days of age, favorable histology, DNA index >1, MYCN not amplified | | :* Patients with stage 3 tumor, ≥ 547 days of age, unfavorable histology, ''MYCN'' not amplified |
| | :* Patients with stage 4 tumor, 365-547 days of age, unfavorable histology, DNA index=1, ''MYCN'' not amplified |
| | :* Patients with stage 4 tumor, >547 days of age, irrespective the grade, ''MYCN'' amplification state |